Semaglutide For Weight Management Does Not Increase Risk Of Mental Health Issues

People taking semaglutide as treatment for weight management did not have higher risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders. During clinical trials to test semaglutide at a 2.4 mg dose as treatment for obesity, 1% or fewer participants reported suicidal ideation or behavior during treatment, with no differences between those taking semaglutide and those taking a placebo. In total, 2.8% of the semaglutide-treated participants and 4.1% of those who received a placebo reported levels of depression at some point during treatment that required evaluation by a . . .